SynapCell and Motac Neuroscience have discovered a new biomarker for monitoring the progression of Parkinson’s disease (PD). The BetaPark [evo] could enable opportunities for drug developers to test the neuroprotective or disease-modifying effects of their compounds. This discovery, combining Motac’s disease modeling and SynapCell’s EEG phenotyping capabilities, was presented in a poster in the Circuit Mechanisms of Motor Dysfunction in Parkinson's Disease Session of the Society for Neuroscience Annual Meeting in Chicago.
BetaPark [evo] will be commercially available to the pharmaceutical industry for PD preclinical drug discovery by Q2 2020.
“Neuronal degeneration begins years before clinical symptoms of Parkinson’s appear. And until now there have been no reliable animal models with relevant biomarkers to track disease progression and screen novel therapies,” says Yann Roche, Ph.D., Chief Innovation Officer at SynapCell. “With BetaPark [evo], we are proud to announce the identification of the first EEG biosignature to address the evolution of Parkinson’s disease and support pharmaceutical companies in developing neuroprotective strategies using objective, accurate and longitudinal metrics over time.”
SynapCell’s Cue® EEG methodologies have successfully highlighted aberrant Beta oscillations (BetaPark) as an in vivo biomarker to assess pharmacodynamics of anti-PD and anti-dyskinetic drug candidates in symptomatic rat models of PD since 2013. The goal of the two-year partnership between the two companies was to phenotype Motac’s Alpha-Synuclein rat model of PD progression using SynapCell’s Cue® EEG technology.
Research conducted through this partnership demonstrated the progressive rise of aberrant Beta synchronization over 12 weeks, alongside with disease progression in the clinically-relevant Alpha-Synuclein rat model. A correlation between neuron loss in the substantia nigra and the increase of BetaPark power was found. Moreover, when treated with L-DOPA, animals revealed a statistically significant decrease of BetaPark power, confirming that the biomarker is pharmacosensitive to this standard-of-care.
BetaPark [evo] could represent a clinically meaningful endpoint for the validation of neuroprotective experimental therapeutics, calling for clinical validation of this surrogate biomarker for neurodegenerative disorders.
https://www.technologynetworks.com/tn/product-news/new-biomarker-of-parkinsons-disease-progression-327961
Dr Noah holistic healing herbal medicine is the best to treat Parkinson disease, i have been batheling this deadly disease for years now knowing full well my days are numbered. My Doctor prescribed some medication for me (Levodopa) which I was taking to help subdue the disease, at a point I was off my meds and the disease started to kick in.
ReplyDeleteI decided to do research for an alternative cure which leads me to a blog where a patient was testifying about Dr Noah herbs, i was overwhelmed and ought to give it a try. To my greatest surprise i am free from parkinson with no much talk get in touch with Dr Noah via:
Email: dr.noahmedicalcenter@gmail.com
Call +1 310 982-4670
Visit website: https://noahmedicalcentre.webs.com/
i was diagnosed of parkinson disease 5 years ago,i started azilect,then mirapex as the disease progressed in february last year,and i started on parkinson disease Herbal medicine from ultimate herbal home,few months into the treatment i made a significant recovery,almost all my symptoms are gone,great improvement with my movement and balance,it been a year and life has been so good for me,contact them at ultimatehealthhome@gmail.com
ReplyDelete